insulin aspart Fiasp
Selected indexed studies
- [Faster aspart insulin (FIASP®)]. (Rev Med Liege, 2018) [PMID:29676875]
- Fiasp--another insulin aspart formulation for diabetes. (Med Lett Drugs Ther, 2018) [PMID:29294464]
- [Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)]. (Medicina (B Aires), 2022) [PMID:36220033]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. (2019) pubmed
- Insulin. (2006) pubmed
- [Faster aspart insulin (FIASP®)]. (2018) pubmed
- Fiasp--another insulin aspart formulation for diabetes. (2018) pubmed
- [Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)]. (2022) pubmed
- Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed(TM) 670G hybrid closed-loop system in simulated trials compared to NovoLog®. (2021) pubmed
- Fast-Acting Insulin Aspart Use with the MiniMed(TM) 670G System. (2021) pubmed
- Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes. (2025) pubmed
- Efficacy and safety of faster aspart in insulin pumps in children and adolescents with type 1 diabetes mellitus: A single-center study with real-world data. (2023) pubmed
- [Faster Insulin Aspart - a new prandial insulin analogue]. (2017) pubmed